Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Май 22, 2025
The
decline
in
neutralizing
antibody
(nAb)
titers
and
vaccine
efficacy
/effectiveness
(VE)
for
SARS-CoV-2
vaccines
has
been
observed
over
time
when
confronted
with
emerging
variants,
two
factors
that
are
hard
to
distinguish.
Despite
substantial
drop
nAb
against
Omicron,
VE
remains
high
severe
cases
fatalities,
raising
questions
about
the
utility
of
detected
nAbs
as
a
correlate
protection
COVID-19
varying
disease
severity.
Here,
we
conducted
systematic
comparison
waning
dynamics
variants
levels
Using
Bayesian
linear
regression
models,
found
antigenically-shifted
like
could
potentially
lead
greater
reductions
primary
mild
infections
than
associated
immunity
180-day
period.
By
comparing
model
predicted
on
same
scales,
fatal
outcomes
remained
above
75%
even
reached
detectable
limit
assays,
despite
strong
correlations
(spearman
≥0.7)
across
time.
This
finding
suggested
not
always
sensitive
enough
fully
predict
death
from
SARS-CoV-2.
Язык: Английский
Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 5, 2024
This
study
examines
the
humoral
and
cellular
response
in
multiple
sclerosis
(MS)
patients
on
anti-CD20
therapy
before
after
1st
to
4th
BNT162b2
mRNA
SARS-CoV-2
vaccination
relationship
with
breakthrough
infection.
Язык: Английский
Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial
EClinicalMedicine,
Год журнала:
2023,
Номер
64, С. 102231 - 102231
Опубликована: Сен. 21, 2023
Heterologous
vaccine
schedules
have
been
recommended
to
provide
superior
immunity
and
protection
against
emergent
SARS-CoV-2
variants
of
concern.
We
aimed
evaluate
the
safety,
immunogenicity,
efficacy
an
mRNA
COVID-19
RQ3013
compared
with
adenoviral
vectored
Ad5-nCoV
protein
subunit
ZF2001
as
fourth
dose
in
adults
primed
three
doses
inactivated
vaccines
China.
Язык: Английский
Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
Vaccines,
Год журнала:
2023,
Номер
11(6), С. 1117 - 1117
Опубликована: Июнь 19, 2023
IgA
plays
a
crucial
role
in
early
virus
neutralization.
To
identify
the
stimulation
by
COVID-19
vaccine,
this
study
aimed
to
evaluate
level
of
anti-S1
serum
participants
immunized
with
different
vaccination
regimens.
Sera
from
567
eligible
vaccinated
two,
three,
or
four
doses
types
vaccine
were
recruited.
Post-vaccine
responses
significantly
varied
according
type
and
regimen.
The
finding
showed
that
heterologous
boosters,
especially
after
priming
an
inactivated
elicited
higher
levels
than
homologous
boosters.
Vaccination
SV/SV/PF
produced
highest
among
all
immunization
regimens
either
doses.
routes
amounts
used
for
non-significant
differences
levels.
After
third
dose
4
months,
decreased
found
on
day
28
both
SV/SV/AZ
groups.
In
conclusion,
our
booster
serum,
vaccine.
presented
may
have
advantages
preventing
SARS-CoV-2
infection
severe
disease.
Язык: Английский
Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
Human Vaccines & Immunotherapeutics,
Год журнала:
2023,
Номер
19(3)
Опубликована: Ноя. 28, 2023
Heterologous
vaccination
with
inactivated
vaccine
followed
by
adenoviral
vector-based
has
shown
superiority
in
enhancing
immune
response
compared
to
homologous
primary
series.
However,
data
comparing
immunity
decline
after
a
third
booster
following
heterologous
CoronaVac/ChAdOx-1nCov-19
been
limited.
Here,
we
assessed
neutralizing
activity
against
omicron
variant
and
T
cell
at
3
months
monitoring
96
individuals
who
received
ChAdOx-1nCov-19,
BNT162b2,
or
mRNA-1273
as
dose
CoronaVac/ChAdOx-1nCov-19.
Comparing
the
antibody
levels
1
month(s)
booster,
results
showed
persistence
of
anti-RBD
IgG
all
regimens,
level
waning
slower
ChAdOx-1nCov-19
boosted
group
(geometric
mean
ratio
(GMR):
0.64
(95%CI:
0.59–0.70))
BNT162b2
(0.34
(95%CI:0.31–0.38))
groups
(0.32
0.29–0.36)).
Neutralizing
BA.2
BA.4/5
dropped
1.2
1.5-fold
but
remained
detectable,
highest
observed
group,
groups,
respectively.
Furthermore,
number
reactivity
decreased
while
it
increased
3-month
post-boost
month.
Data
on
durability
could
help
comprehensively
optimize
strategy.
Язык: Английский